Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Cited by (1,006)

Items 201–300 of 1,006

1. Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand
   Florian Scotté, J.M. Tourani, Eugéniu Banu, Michel Peyromaure, Eric Levy, Sandrine Marsan, Emmanuelle Magherini, Elizabeth Fabre, Jean‐Marie Andrieu, Stéphane Marie. Oudard · 2005 · Journal of Clinical Oncology
2. Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
   Marc Dror Michaelson, Stéphane Marie. Oudard, Yen-Chuan Ou, Lisa Sengeløv, Fred Saad C, Nadine Houédé, Peter James Ostler, Arnulf Stenzl, Gedske Daugaard, Robert J. Jones et al. · 2013 · Journal of Clinical Oncology
3. The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer
   Pond, Gregory R., Sonpavde, Guru, de Wit, Ronald, Eisenberger, Mario A., Tannock, Ian F., Armstrong, Andrew J. · 2014 · European Urology
4. Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer
   Susan Halabi, Nicholas J. Vogelzang, Alice B. Kornblith, San‐San Ou, Philip W. Kantoff, Nancy Ann Dawson, Eric Jay Small · 2008 · Journal of Clinical Oncology
5. A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer
   Robert S. DiPaola, MARK K. PLANTE, Howard L. Kaufman, DP Petrylak, Ron Israeli, Edmund C. Lattime, Kelledy H. Manson, Thomas J. Schuetz · 2006 · Journal of Translational Medicine
6. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
   Yohann Loriot, Kurt Miller, Cora Nanette Sternberg, Karim S. Fizazi, Johann Sebastian De Bono, Simon Chowdhury, Celestia S. Higano, Sarah B. Noonberg, Stefan Holmström, Harry H. Mansbach et al. · 2015 · The Lancet Oncology
7. CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy
   Urszula Domańska, Hetty Timmer‐Bosscha, Wouter Bastiaan Nagengast, Thijs H. Oude Munnink, Roeliene C. Kruizinga, Hildo J.K. Ananias, Nathalie M. Kliphuis, Gerwin A. Huls, Elisabeth G.E. de Vries, Igle Jan de Jong et al. · 2012 · Neoplasia
8. Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer
   Matthew D. Galsky, Eric Jay Small, William K. Oh, Isan Chen, David Carl Smith, Alexander Dimitrios Colevas, Lou Martone, Tracy Curley, A. Delacruz, Howard I. Scher et al. · 2005 · Journal of Clinical Oncology
9. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer
   Dylan Michael Zylla, Brett L. Gourley, Derek Vang, Scott Jackson, Sonja M. Boatman, Bruce R. Lindgren, Michael A. Kuskowski, Chap T. Le, Kalpna Gupta, Pankaj Gupta · 2013 · Cancer
10. Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation
    Chang‐Shi Chen, Yu-Chieh Wang, Meihua Yang, Po-Hsien Huang, Samuel Kiyota Kulp, Chih-Cheng Yang, Yen‐Shen Lu, Shigemi Matsuyama, Ching‐Yu Chen, Ching‐Shih Chen · 2007 · Cancer Research · Retracted
11. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
    Kambiz Rahbar, Axel Bode, Matthias Weckesser, Nemanja Avramović, Michael Claesener, Lars Stegger, Martin Bögemann · 2016 · Clinical Nuclear Medicine
12. A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
    Elisabeth I. Heath, David W. Hillman, Ulka N. Vaishampayan, Shijie Sheng, Fazlul H. Sarkar, Felicity W. K. Harper, Melvin Gaskins, Henry Clement Pitot, Winston W. Tan, S. Percy Ivy et al. · 2008 · Clinical Cancer Research
13. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials
    Duminda Nalaka Wijeysundera, Peter C. Austin, Janet E. Hux, William Scott Beattie, Andreas Laupacis · 2008 · Journal of Clinical Epidemiology
14. Immune Infiltration and Prostate Cancer
    Amy Strasner, Michael Karin · 2015 · Frontiers in Oncology
15. Advances in Prostate Cancer Chemotherapy: A New Era Begins
    Kenneth J. Pienta, David Carl Smith · 2005 · CA A Cancer Journal for Clinicians
16. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
    Finn Edler von Eyben, Giandomenico Roviello, Timo Kiljunen, Christian Uprimny, Irene Johanna Virgolini, Kalevi Kairemo, Timo K. Joensuu · 2017 · European Journal of Nuclear Medicine and Molecular Imaging
17. Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins
    Marianne S. Poruchynsky, Edina Komlódi-Pásztor, Shana Y. Trostel, Julia Wilkerson, Marie Regairaz, Yves G. Pommier, Xu Zhang, Tapan Kumar Maity, Robert W. Robey, Mauricio Burotto et al. · 2015 · Proceedings of the National Academy of Sciences
18. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
    L. Rhoda Molife, Gerhardt Attard, Peter C.C. Fong, Vasilios Karavasilis, Alison H. M. Reid, Stephen G. Patterson, Charles E. Riggs, Celestia S. Higano, Walter Michael Stadler, William F. McCulloch et al. · 2009 · Annals of Oncology
19. The role of Src in prostate cancer
    Karim S. Fizazi · 2007 · Annals of Oncology
20. Radioligand Therapy With 177 Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Sada Nand Dwivedi, Chandrasekhar Bal · 2019 · American Journal of Roentgenology
21. Both Microtubule-Stabilizing and Microtubule-Destabilizing Drugs Inhibit Hypoxia-Inducible Factor-1α Accumulation and Activity by Disrupting Microtubule Function
    Daniel Escuín, Erik R. Kline, Paraskevi Giannakakou · 2005 · Cancer Research
22. Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer
    Antonarakis, Emmanuel S., Heath, Elisabeth I., Smith, David C., Rathkopf, Dana, Blackford, Amanda L., Danila, Daniel C., King, Serina, Frost, Anja, Ajiboye, A. Seun, Zhao, Ming et al. · 2013 · The Oncologist
23. Prostate cancer in the elderly
    Emil Scosyrev, Edward M. Messing, Supriya Gupta Mohile, Dragan Golijanin, Guan Wu · 2011 · Cancer
24. An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
    Glenn Liu, William Kevin Kelly, George Wilding, Lance Howard Leopold, Kimberli J. Brill, Bradley G. Somer · 2009 · Clinical Cancer Research
25. Targeting Continued Androgen Receptor Signaling in Prostate Cancer
    Christophe Massard, Karim S. Fizazi · 2011 · Clinical Cancer Research
26. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States
    Daniel J. George, Oliver A. Sartor, Kurt Miller, Fred Saad C, Bertrand F. TOMBAL, Ján Kalinovský, Xiaolong Jiao, Krishna Tangirala, Cora Nanette Sternberg, Celestia S. Higano · 2020 · Clinical Genitourinary Cancer
27. Metabolic alterations and targeted therapies in prostate cancer
    Richard Flavin, Giorgia Zadra, Massimo F. Loda · 2010 · The Journal of Pathology
28. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‐resistant nonmetastatic prostate cancer
    Matthew R. Smith, Richard J. Cook, Ker‐Ai Lee, Joel B. Nelson · 2010 · Cancer
29. Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients
    Jonathan E. Rosenberg, VIVIAN K. WEINBERG, William Kevin Kelly, Marc Dror Michaelson, Maha Hussain, George Wilding, Mitchell Eric Gross, Douglass Hutcheon, Eric Jay Small · 2007 · Cancer
30. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose
    Hirotsugu Kenmotsu, Yusuke Tanigawara · 2015 · Cancer Science
31. A population study of neutering status as a risk factor for canine prostate cancer
    Jeffrey N. Bryan, Matthew R. Keeler, Carolyn J. Henry, Margaret E. Bryan, Allen W. Hahn, Charles W. Caldwell · 2007 · The Prostate
32. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
    Mari I. Suominen, Katja M. Fagerlund, Jukka P. Rissanen, Yvonne M. Konkol, Jukka P. Morko, Zhiqi Peng, Esa J. Alhoniemi, Salla K. Laine, Eva Corey, Dominik Mumberg et al. · 2017 · Clinical Cancer Research
33. Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis
    Guccini, Ilaria, Revandkar, Ajinkya, D'Ambrosio, Mariantonietta, Colucci, Manuel, Pasquini, Emiliano, Mosole, Simone, Troiani, Martina, Brina, Daniela, Sheibani-Tezerji, Raheleh, Elia, Angela Rita et al. · 2021 · Cancer Cell
34. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer
    Hofland, Johannes, van Weerden, Wytske M., Dits, Natasja F.J., Steenbergen, Jacobie, van Leenders, Geert J.L.H., Jenster, Guido, Schröder, Fritz H., de Jong, Frank H. · 2010 · Cancer Research
35. Vitamin D: Considerations in the Continued Development as an Agent for Cancer Prevention and Therapy
    Donald L. Trump, Kristin K. Deeb, Candace S. Johnson · 2010 · The Cancer Journal
36. Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based Chemotherapy
    Tateki Yoshino, Hiroaki Shiina, Shinji Urakami, Nobuyuki Kikuno, Tatsuaki Yoneda, Kazushi Shigeno, Mikio Igawa · 2006 · Clinical Cancer Research
37. Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer
    Phillip G. Febbo, Jerome P. Richie, Daniel J. George, Massimo F. Loda, Judith B. Manola, Sridhar Shankar, Agnieska Szot Barnes, Clare M. Tempany, William J. Catàlona, Philip W. Kantoff et al. · 2005 · Clinical Cancer Research
38. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
    The JACCRO and KCSG Study Group, Wasaburo Koizumi, Yeul Hong Kim, Masashi Fujii, Hoon Kyo Kim, Hiroshi Imamura, Kyung Hee Lee, Takuo Hara, Hyun Cheol Chung, Taroh Satoh et al. · 2013 · Journal of Cancer Research and Clinical Oncology
39. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
    Kristine M. Wadosky, Shahriar Koochekpour · 2016 · Oncotarget
40. Inflammation and cancer
    Noemí Eiró · 2012 · World Journal of Gastrointestinal Surgery
41. Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer
    Karim S. Fizazi, Philippe Beuzeboc, J. Lumbroso, Vincent Haddad, Christophe Massard, Marine Gross‐Goupil, Mario Di Palma, Bernard J. Escudier, Christine Théodore, Yohann Loriot et al. · 2009 · Journal of Clinical Oncology
42. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
    Martin Puhr, Julia Hoefer, Andrea Eigentler, Christian Ploner, Florian Handle, Georg Schaefer, Jan Kroon, Angela Leo, Isabel Maria Heidegger, Iris Elisabeth Eder et al. · 2017 · Clinical Cancer Research
43. SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis
    Xun Shangguan, Jianli He, Zehua Ma, Weiwei Zhang, Yiyi Ji, Kai Shen, Zhiying Yue, Wenyu Li, Zhixiang Xin, Quan Zheng et al. · 2021 · Nature Communications
44. A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer
    Christopher J. Sweeney, Glenn Liu, Constantin Theodore Yiannoutsos, Jill Kolesar, Dorothea L. Horvath, Mary Jane Staab, Karen Fife, Victoria Armstrong, Anthony M. Treston, Carolyn Fowler Sidor et al. · 2005 · Clinical Cancer Research
45. Targeting minimal residual disease: a path to cure?
    Marlise Rachael Luskin, Mark Alan Murakami, Scott R. Manalis, David M. Weinstock · 2018 · Nature reviews. Cancer
46. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
    Michael Froehner, Manfred Peter Wirth · 2014 · New England Journal of Medicine
47. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review
    Matthieu Picard, Mariana Castells · 2014 · Clinical Reviews in Allergy & Immunology
48. Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
    Paul Gustav Kluetz, William F. Pierce, Virginia Ellen Maher, Hui Zhang, Shenghui W. Tang, Pengfei Song, Qi Liu, Martin T. Haber, Eldon E. Leutzinger, Ali H. Al-Hakim et al. · 2013 · Clinical Cancer Research
49. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
    Andrew J. Armstrong, Ping Lin, Bertrand F. TOMBAL, Fred Saad C, Celestia S. Higano, Anthony Michael Joshua, Teresa Parli, Brad Rosbrook, Steve van Os, Tomasz M. Beer · 2020 · European Urology
50. The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
    Saroj Niraula, Boštjan Šeruga, Alberto Ocaña, Tiffany Shao, Robyn Goldstein, Ian F. Tannock, Eitan Amir · 2012 · Journal of Clinical Oncology
51. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
    Chi, K.N., Kheoh, T., Ryan, C.J., Molina, A., Bellmunt, J., Vogelzang, N.J., Rathkopf, D.E., Fizazi, K., Kantoff, P.W., Li, J. et al. · 2016 · Annals of Oncology
52. Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity
    Josep M. Domingo Domenech, Cristina Oliva, Ana Rovira, Jordi Codony‐Servat, Marta Bosch, Xavier Filella, Clara O. Montagut, Marian Tápia, Clara Campàs, Lenny Dang et al. · 2006 · Clinical Cancer Research
53. Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer
    Henry K. Tsai, Ming‐Hui Chen, David G. McLeod, Peter R. Carroll, Jerome P. Richie, Anthony Victor D'Amico · 2006 · Cancer
54. A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer
    Anthony W. Tolcher, Kim Chi, John G. Kuhn, Martin Edwin Gleave, Amita Patnaik, Chris H.M. Takimoto, Garry H. Schwartz, Ian Murchie Thompson, Kristin Berg, Susan D’Aloisio et al. · 2005 · Clinical Cancer Research
55. Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer
    Hildo J.K. Ananias, Marius Christianus van den Heuvel, Wijnand Helfrich, Igle Jan de Jong · 2009 · The Prostate
56. Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
    Grazia Graziani, Lucio Tentori, Pierluigi Navarra · 2011 · Pharmacological Research
57. Metastatic prostate cancer remains incurable, why?
    Liang Dong, Richard C. Zieren, Wei Xue, Theo M. de Reijke, Kenneth J. Pienta · 2018 · Asian journal of urology
58. Reshaping Prostate Tumor Microenvironment To Suppress Metastasis via Cancer-Associated Fibroblast Inactivation with Peptide-Assembly-Based Nanosystem
    Jiayan Lang, Xiao Zhao, Yingqiu Qi, Yinlong Zhang, Xuexiang Han, Yanping Ding, Jiajing Guan, Tianjiao Ji, Ying Zhao, Guangjun Nie · 2019 · ACS Nano
59. TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
    Michael S. Hofman, Louise Emmett, John A. Violet, Alison Yan Zhang, Nicola Jane Lawrence, Martin R. Stockler, Roslyn J. Francis, Amir Iravani, Scott Williams, Arun Azad et al. · 2019 · British Journal of Urology
60. Clinical Pharmacokinetics of Docetaxel
    Sharyn D. Baker, Alex Sparreboom, Jaap Verweij · 2006 · Clinical Pharmacokinetics
61. New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety
    Himisha Beltran, Tomasz M. Beer, Michael Anthony Carducci, Johann Sebastian De Bono, Martin Edwin Gleave, Maha Hussain, William Kevin Kelly, Fred Saad C, Cora Nanette Sternberg, Scott T. Tagawa et al. · 2011 · European Urology
62. Guidelines for the management of castrate-resistant prostate cancer
    Fred Saad C, Sebastién J. Hotte · 2010 · Canadian Urological Association Journal
63. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression
    Kazumasa Komura, Seong Ho Jeong, Kunihiko Hinohara, Fangfang Qu, Xiaodong Wang, Masayuki Hiraki, Haruhito Azuma, Gwo‐Shu Mary Lee, Philip W. Kantoff, Christopher J. Sweeney · 2016 · Proceedings of the National Academy of Sciences
64. Curcumin against Prostate Cancer: Current Evidence
    Deborah Termini, Danja J. Den Hartogh, Alina Jaglanian, Evangelia Tsiani · 2020 · Biomolecules
65. Autophagy as a modulator and target in prostate cancer
    Jason Michael Farrow, Joy C. Yang, Christopher P. Evans · 2014 · Nature Reviews Urology
66. Granulocyte-macrophage colony-stimulating factor−transduced allogeneic cancer cellular immunotherapy: The GVAX® vaccine for prostate cancer
    Jonathan W. Simons, Natalie Sacks · 2006 · Urologic Oncology Seminars and Original Investigations
67. Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
    Guillaume Ploussard, Stéphane Terry, Pascale Maillé, Yves Allory, Nanor Sirab, Laurence Kheuang, Pascale Soyeux, Nathalie Nicolaı̈ew, Estelle Coppolani, Bernard Paule et al. · 2010 · Cancer Research
68. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
    David I. Quinn, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Amir Goldkorn, Carol M. Moinpour, Mark G. Garzotto, Philip C. Mack, Michael Anthony Carducci, J. Paul Monk et al. · 2013 · The Lancet Oncology
69. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1
    Yuan Wang, Rachel Lieberman, Jing Pan, Qi Zhang, Meijun Du, Peng Zhang, Marja T. Nevalainen, Manish Kohli, Niraj Konchady Shenoy, Hui Meng et al. · 2016 · Molecular Cancer
70. Breast Cancer, Version 1.2016
    William John Gradishar, Benjamin O. Anderson, Ronald Balassanian, Sarah L. Blair, Harold J. Burstein, Amy E. Cyr, ANTHONY D. ELIAS, William Blair Farrar, Andres Forero, Sharon Hermes Giordano et al. · 2015 · Journal of the National Comprehensive Cancer Network
71. Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
    Nicholas David James, Armelle Caty, Michael Borre, Bernard A. Zonnenberg, Philippe Beuzeboc, Thomas Morris, De Phung, Nancy Ann Dawson · 2008 · European Urology
72. Ixabepilone (Epothilone B Analogue BMS-247550) Is Active in Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer: A Southwest Oncology Group Trial S0111
    Maha Hussain, Catherine M. Tangen, Primo N. Lara, Ulka N. Vaishampayan, Daniel Peter Petrylak, Alexander Dimitrios Colevas, Wael Sakr, Elward David Crawford · 2005 · Journal of Clinical Oncology
73. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis
    Lechen Li, Amir H. Ameri, Simeng Wang, Keith H. Jansson, Orla M. Casey, Qi Yang, Michael L. Beshiri, Lei Fang, Ross G. Lake, Supreet Agarwal et al. · 2019 · Oncogene
74. Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
    Prabhakar Rajan, Ian M. Sudbery, M. Eugenia M. Villasevil, Ernest J. Mui, Janis Fleming, Mark Davis, Imran Ahmad, Joanne Edwards, Owen James Sansom, David Sims et al. · 2013 · European Urology
75. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies
    Vanna Sanna, Anna Maria Roggio, Anna Maria Posadino, Annalisa Cossu, Salvatore Marceddu, Alberto Mariani, Valeria Alzari, Sergio Uzzau, Gianfranco Pintus, Mario Sechi · 2011 · Nanoscale Research Letters
76. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Alan Horwich, Chris C. Parker, Theo M. de Reijke, Vesa V Kataja · 2013 · Annals of Oncology
77. Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
    M. L. Huber, L. Haynes, Chris C. Parker, Peter Iversen · 2012 · JNCI Journal of the National Cancer Institute
78. Mechanisms of Therapeutic Resistance in Prostate Cancer
    Mari Nakazawa, Channing Judith Paller, Natasha Kyprianou · 2017 · Current Oncology Reports
79. Metastatic Prostate Cancer: Treatment Options
    Vérane Achard, Paul Martin Putora, Aurelius Gabriel Omlin, Thomas Zilli, Stefanie Fischer · 2021 · Oncology
80. Secondary Hormonal Therapy for Advanced Prostate Cancer
    Lam, John S., Leppert, John T., Vemulapalli, Sreenivas N., Shvarts, Oleg, Belldegrun, Arie S. · 2006 · Journal of Urology
81. Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
    Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Òscar Reig, Juan José Lozano, Pedro Luis Fernández, María Verónica Pereira, Natàlia Jiménez, Michael Joseph Donovan, Pere Puig, Lourdes Mengual et al. · 2014 · Molecular Cancer Therapeutics
82. Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import
    Verónica Rodríguez-Bravo, Raffaella Pippa, Won-Min Song, Marc Carceles‐Cordon, Ana Dominguez-Andres, Naoto Fujiwara, JungReem Woo, Anna P. Koh, Adam Ertel, Ravi K. Lokareddy et al. · 2018 · Cell
83. Phase II study of sunitinib in men with advanced prostate cancer
    Marc Dror Michaelson, Meredith M. Regan, William K. Oh, Donald S. Kaufman, Kara Marie Olivier, Simon Michaelson, Beverly Spicer, Carol Gurski, Philip W. Kantoff, Matthew Raymond Smith · 2009 · Annals of Oncology
84. Update on tubulin-binding agents
    Gerhardt Attard, Alastair Greystoke, Stan B. Kaye, Johann Sebastian De Bono · 2005 · Pathologie Biologie
85. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
    Bernhard Grubmüller, Daniela Senn, Gero Kramer, Pascal Baltzer, David D’Andrea, Karl Hermann Grubmüller, Markus Mitterhauser, Harald Eidherr, Alexander Robert Haug, Wolfgang Wadsak et al. · 2018 · European Journal of Nuclear Medicine and Molecular Imaging
86. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
    Seth A. Rosenthal, Chen Hu, Oliver A. Sartor, Leonard G. Gomella, Mahul B. Amin, James A. Purdy, Jeff M. Michalski, Mark G. Garzotto, Nadeem Pervez, Alexander G. Balogh et al. · 2019 · Journal of Clinical Oncology
87. Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
    Ugo Testa, Germana Castelli, Elvira Pelosi · 2019 · Medicines
88. Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype
    Robert D. Loberg, Christopher J. Logothetis, Evan T. Keller, Kenneth J. Pienta · 2005 · Journal of Clinical Oncology
89. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
    Matthew Robert Sydes, Mahesh Parmar, Nicholas David James, Noel William Clarke, David Paul Dearnaley, Malcolm David Mason, Rachel C. Morgan, Karen Sanders, Patrick J Royston · 2009 · Trials
90. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel
    Pedram Kharaziha, Dimitris Chioureas, Dorothea Rutishauser, George Baltatzis, Lena Lennartsson, Pedro Fonseca, Alireza Azimi, Kjell R. Hultenby, Roman A. Zubarev, Anders Ullén et al. · 2015 · Oncotarget
91. Satraplatin: leading the new generation of oral platinum agents
    Ashish Bhargava, Ulka N. Vaishampayan · 2009 · Expert Opinion on Investigational Drugs
92. Dasatinib combined with docetaxel for castration‐resistant prostate cancer
    John C. Araujo, Paul F. Mathew, Andrew J. Armstrong, Edward Louis Braud, Edwin M. Posadas, Mathew Lonberg, Gary E. Gallick, Geralyn Carol Trudel, Prashni Paliwal, Shruti Agrawal et al. · 2011 · Cancer
93. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
    Daniel Peter Petrylak, Nicholas J. Vogelzang, Nikolay Budnik, Paweł Wiechno, Cora Nanette Sternberg, Kevin Doner, Joaquim Bellmunt B, John M. Burke, María Ochoa de Olza, Ananya Choudhury et al. · 2015 · The Lancet Oncology
94. Sequencing of agents in castration-resistant prostate cancer
    David Lorente, Joaquı́n Mateo, Raquel Pérez-López, Johann Sebastian De Bono, Gerhardt Attard · 2015 · The Lancet Oncology
95. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
    Luca Triggiani, Filippo Alongi, Michela Buglione, Beatrice Detti, Riccardo Santoni, Alessio Bruni, Ernesto Maranzano, Frank Lohr, Rolando Maria D’Angelillo, Alessandro Magli et al. · 2017 · British Journal of Cancer
96. Guía de la EAU para el Cáncer de Próstata
    Axel Heidenreich, Gunna Aus, M. Bolla, Steven Joniau, Vsevolod B. Matveev, Schmid, Hans Peter, Filliberto Zattoni, European Association of Urology · 2009 · Hispana
97. Chemotherapy for hormone-refractory prostate cancer
    Mike D. Shelley, Craig Harrison, Bernadette Coles, John Stafforth, Timothy J Wilt, Malcolm David Mason · 2006 · Cochrane Database of Systematic Reviews
98. Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
    Maria Thadani‐Mulero, David M. Nanus, Paraskevi Giannakakou · 2012 · Cancer Research
99. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells
    Guohai Shi, Dingwei Ye, Xu-Dong Yao, Shi-ling Zhang, Bo Dai, Hai‐Liang Zhang, Yi-jun Shen, Yao Zhu, Yiping Zhu, Wen-jun Xiao et al. · 2010 · Acta Pharmacologica Sinica
100. Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
     Jack A. Schalken, John M. Fitzpatrick · 2015 · British Journal of Urology